BioSpace News Archive

Merck, known as MSD outside the United States and Canada, and the Merck Foundation announced the company will make an additional commitment of $10 million in support of COVID-19 relief efforts to help address health disparities and inequality among patients and communities.

NovaBay® Pharmaceuticals, Inc. announces the appointment of Andrew D. Jones as Chief Financial Officer and Treasurer, effective May 1, 2020.

TransEnterix, Inc. announced that it plans to release first quarter financial and operating results before the market opens on Thursday, May 14, 2020.

Amicus Therapeutics a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases announced the acceptance of several abstracts for presentation at the American Society of Gene & Cell Therapy 23rd Annual Meeting being held virtually on May 12 – 15.

Antares Pharma, Inc., reported operating and financial results for the first quarter ended March 31, 2020 with record first quarter revenue of $33.1 million and a net loss per share of $0.01.

Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Development & Operations, effective immediately.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced it will host a conference call and webcast on Tuesday, May 12, 2020 at 8:30 AM Eastern Time to discuss its first quarter 2020 operating and financial results.

Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen

Resonant Inc., a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, is scheduled to participate in the virtual Oppenheimer 5th Annual Emerging Growth Conference on May 12, 2020.

Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients